Verrica Pharmaceuticals Inc.VRCANASDAQ
LOADING
|||
Switch Symbol:
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -161.06% | -82.70% | -10.12% | +145.35% | +0.00% |
| Gross Profit Growth | -179.94% | +0.00% | +12.20% | +166.71% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.59% | +45.38% | +104.02% | +104.03% | +102.76% |
| Weighted Average Shares Diluted Growth | +1.59% | +45.38% | +104.02% | +104.09% | +102.76% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -97.94% | -98.26% | -25.56% | +70.17% | +8625.00% |
| Inventory Growth | +826.16% | +141.00% | -1.60% | -6.73% | -10.84% |
| Asset Growth | -66.11% | -33.66% | -36.39% | -24.81% | +24.20% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +7.52% | +0.94% | -8.64% | -16.02% | -24.15% |
| R&D Expense Growth | -63.06% | -78.06% | -53.84% | -44.38% | -8.32% |
| SG&A Expenses Growth | -19.80% | -41.88% | -45.85% | -46.42% | -41.53% |